CONFLICTS OF INTEREST

C. Pouplard received consulting and travel fees from Sobi, Roche, Novo Nordisk and CSL Behring. C. Ternisien received consulting and travel fees from Sobi, Roche and Octapharma. A. Ryman received travel fees from Sobi, Novo Nordisk and CSL Behring. Y. Respesse received consulting and travel fees from Shire, Octapharma, Pfizer, LFB and Roche. F. Grand received travel fees from Octapharma and Sobi. E. Jeanpierre received travel fees from Novo Nordisk, Shire, Roche and Sobi. C Nougier received travel fees from Sobi, CSL, Novo Nordisk, Roche and Octapharma. D Lasne received travel fees from Sobi, CSL, Novo Nordisk, Roche, Octapharma and Werfen. A Ryman received travel fees from Sobi, CSL, Pfizer, LFB, Novo Nordisk, Roche and Octapharma. A Serre Sapin received travel fees from Sobin CSL, LFB, Octapharma and Werfen. All the authors did not receive any personal honorarium or funds related to the study reported in this manuscript.

C. Pouplard received consulting and travel fees from Sobi, Roche, Novo Nordisk and CSL Behring. C. Ternisien received consulting and travel fees from Sobi, Roche and Octapharma. A. Ryman received travel fees from Sobi, Novo Nordisk and CSL Behring. Y. Respesse received consulting and travel fees from Shire, Octapharma, Pfizer, LFB and Roche. F. Grand received travel fees from Octapharma and Sobi. E. Jeanpierre received travel fees from Novo Nordisk, Shire, Roche and Sobi. C Nougier received travel fees from Sobi, CSL, Novo Nordisk, Roche and Octapharma. D Lasne received travel fees from Sobi, CSL, Novo Nordisk, Roche, Octapharma and Werfen. A Ryman received travel fees from Sobi, CSL, Pfizer, LFB, Novo Nordisk, Roche and Octapharma. A Serre Sapin received travel fees from Sobin CSL, LFB, Octapharma and Werfen. All the authors did not receive any personal honorarium or funds related to the study reported in this manuscript.